ClinicalTrials.gg
CompletedNCT06681493Updated Jun 30, 2026

A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects

A Phase 1 interventional study of YZJ-4729 Tartrate injection and YZJ-4729 simulated injection in Postoperative Analgesia, sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Oct 2022, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Part A

Primary objective:

  • To evaluate the safety, tolerability, and pharmacokinetic profile of a single dose of YZJ-4729 tartrate injection.

Secondary objectives:

  • To investigate the PK/PD profile of YZJ-4729 tartrate injection administered as a single dose;
  • To investigate the metabolic transformation characteristics of YZJ-4729 tartrate;
  • To assess the relationship between plasma concentrations and change in QT interval (C-QT) and the effect on QT interval in subjects after a single dose of YZJ-4729 tartrate injection.

Part B

Primary objective:

  • To evaluate the safety, tolerability and pharmacokinetic profile of YZJ-4729 tartrate injection administered at the same dose and at different infusion rates .

Secondary objectives:

  • To investigate the PK/PD profile of YZJ-4729 tartrate injection administered at the same dose and at different infusion rates.
02

Conditions studied

  • Postoperative Analgesia
03

In context

Lead sponsor

Shanghai Haiyan Pharmaceutical Technology Co., Ltd. is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged between 18 and 45 years (inclusive) on the day of signing the ;
  2. Male subjects weighing no less than 50 kg and female subjects weighing no less than 45 kg. within the range 19.0-26.0 kg/m 2 (inclusive);
  3. Subjects in good health without a history of serious diseases and chronic diseases such as respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system and mental system;
  4. From the date of signing the informed consent form until 6 months after the last dose of drug, the subject (including partner) need to have no sperm or egg donation plan or pregnancy plan and voluntarily take effective measures.
  5. Voluntarily need to sign the informed consent form before the trial, and fully understand the content, process and possible adverse reactions of the trial.

Exclusion criteria

Exclusion Criteria:

  1. Medical history of cardiovascular and respiratory system (such as sleep apnea syndrome, pulmonary heart disease or chronic bronchial asthma), liver, kidney, nervous system (such as epilepsy), blood system or mental disorders that the researcher considers ;
  2. Medical history of cardiovascular system disease, including but not limited to history or family history of syncope, coronary heart disease (such as coronary angiography diagnosis of coronary heart disease, history of acute coronary syndrome, history of myocardial infarction, etc.), valvular heart disease, heart failure, history of non-drug-induced bradyarrhythmia, frequent ventricular premature beats, ventricular tachycardia, etc.; or previous prolongation or other risk factors for torsades de pointes (hypokalemia, etc.), or a family history of a first-degree relative (i.e., biological parent, brother, sister or child) with short QT syndrome, long QT syndrome, sudden death of unknown cause in his youth (less than/equal to 40 years old), drowning or sudden infant death syndrome;
  3. Medical history of symptomatic head trauma;
  4. History of frequent nausea or vomiting of any etiology;
  5. Medical history of glaucoma or any condition affecting pupil size;
  6. Major surgery or major trauma within 6 months prior to screening or planning to undergo surgery during the study;
  7. Known to be allergic to two or more kinds of food and drugs;
  8. Known to be allergic to opioids, or have for the use of such drugs;
  9. Difficulties in collecting venous blood, or the cases with known needle and blood sickness history;
  10. Female subjects who are lactating, pregnant, preparing for pregnancy or have the abnormal pregnancy test results with clinical significance at screening;
  11. Clinically significant abnormal findings at screening, such as QTcF ≥ 450 ms in men and QTcF ≥ 470 ms in women; PR interval ≥ 200 ms; QRS complex duration ≥ 120 ms;
  12. Abnormal vital signs at screening (systolic blood pressure \< 90 mmHg or > 140 mmHg, diastolic blood pressure \< 50 mmHg or > 90 mmHg; respiratory \< 16 breaths/min or > 20 breaths/min; pulse \< 60 beats/min or >100 beats/min) or clinically significant abnormal physical examination, laboratory tests (blood routine, urine routine, blood biochemistry, coagulation function), chest anteroposterior view or CT, abdominal color ultrasound (subject to the judgment of clinicians);
  13. Subjects having clinically significant abnormalities in any of virus surface antigen, Treponema pallidum-specific antibody, antibody and virus antibody at screening;
  14. Serum potassium, magnesium and calcium exceeding the reference range or lower limit of normal reference range at screening;
  15. Oxygen saturation less than 95% at screening;
  16. History of any drug abuse within 1 year before screening or positive urine drug test results during screening;
  17. Regular drinkers within 6 months prior to screening (drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits 40% or 150 mL of wine) or breath alcohol test results > 0 mg/100 mL, or having taken any products containing alcohol within 48 hours prior to the first use of drug or not agreeing to refrain from taking any products containing alcohol during the trial;
  18. Smoking more than 5 cigarettes a day within 3 months before screening, or using tobacco products within 48 hours before the first use of investigational drug, or not stopping using any tobacco products during the trial;
  19. Blood donation or massive blood loss (blood loss > 400 mL, excluding female menstrual blood loss), receiving blood transfusion or using blood products within 3 months before screening;
  20. Participation in any clinical trial within 3 months prior to screening;
  21. Attenuated/DNA nucleic acid/recombinant protein vaccination within 4 weeks prior to screening, or inactivated vaccination within 2 weeks prior to screening, or any planned vaccination during the trial;
  22. Any proposed combination of drugs that alter hepatic CYP2C9 and enzyme activities, including potent inhibitors and inducers of enzymes that affect hepatic metabolism or that result in QT/QTc prolongation, 28 days prior to screening or during the trial;
  23. Subjects who have used or are using opioids within 14 days before the first use of investigational drug;
  24. Receiving other prescription or over-the-counter medications considered by the investigator to affect the results of this study evaluation within 14 days prior to the first dose of investigational drug;
  25. Consumption of grapefruit or grapefruit juice or any food or beverage containing grapefruit within 7 days before the first dose of investigational drug, or disagreement to refrain from consumption of such food or beverage during the trial;
  26. Taking or having taken any medication affecting pupil size within 48 hours prior to the first dose of investigational product;
  27. Taking any caffeine-rich food or beverage (coffee, tea, cola, chocolate, etc.) within 48 hours before the first dose of investigational product, or disagreeing to refrain from consuming them during the trial;
  28. Subjects who, in the opinion of the investigator, are not suitable for participation in this clinical trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Part A

    Part A Experimental: YZJ-4729 Tartrate injection; Part A Control: YZJ-4729 simulated injection

    Drug: YZJ-4729 Tartrate injection · Drug: YZJ-4729 simulated injection

  • Experimental
    Part B

    Subjects will receive YZJ-4729 Tartrate injection

    Drug: YZJ-4729 Tartrate injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17

  2. Incidence of participants with clinical laboratory abnormalities

    Time frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17

  3. Incidence of participants with vital signs abnormalities

    Time frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17

  4. Incidence of participants with physical exam abnormalities

    Time frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17

  5. Cmax

    Cmax is defined as the observed maximum plasma concentration.

    Time frame: Pre-dose to 72 hours post-dose

  6. AUCinf

    AUCinf is defined as the area under the plasma concentration-time curve extrapolated to infinity from time zero.

    Time frame: Pre-dose to 72 hours post-dose

  7. AUC0-24h

    AUC0-24h is defined as the area under the plasma concentration-time curve from time zero to 24h.

    Time frame: Pre-dose to 72 hours post-dose

  8. AUC0-t

    AUC0-24h is defined as the area under the plasma concentration-time curve from time zero to the last observable concentration.

    Time frame: Pre-dose to 72 hours post-dose

  9. t1/2z

    t1/2z is defined as the elimination half-life.

    Time frame: Pre-dose to 72 hours post-dose

  10. Tmax

    Tmax is defined as the observed time to reach Cmax.

    Time frame: Pre-dose to 72 hours post-dose

  11. CL

    CL is defined as the clearance.

    Time frame: Pre-dose to 72 hours post-dose

  12. Vz

    V is defined as the apparent volume of distribution.

    Time frame: Pre-dose to 72 hours post-dose

  13. MRT

    MRT is defined as the mean residence time.

    Time frame: Pre-dose to 72 hours post-dose

  14. Ae0-t

    Ae0-t is defined as the cumulative amount of drug excreted in urine or fecal from time zero to the last observable concentration.

    Time frame: Pre-dose to 72 hours post-dose

  15. Cumulative excretion percentage of drug through urine and feces

    Time frame: Pre-dose to 72 hours post-dose

Secondary outcomes

  1. Pupil diameter

    Time frame: Pre-dose to 12 hours post-dose

  2. Change from baseline of QTcF by timepoint

    Time frame: Pre-dose to 24 hours post-dose

07

Study locations

1 site
  • Xiangya Third Hospital, Central South University
    Changsha, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Apr 2023, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 8, 2024
StartActual
Oct 12, 2022
Primary completionActual
Apr 14, 2023
CompletionActual
Sep 22, 2023
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06681493
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Oct 12, 2022
Primary completion
Apr 14, 2023
Completion
Sep 22, 2023
Last update
Jun 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Susineridine

Start the discussion